Pumecitinib

Small moleculeexperimental

Clinical trial activity

3 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0

Earliest trial started Mar 15, 2024 (NCT06587685)

Timeline

2020s

  1. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2025

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)S(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)c(N)n2)C1
Mol. weight
400.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07146126Phase 3Sep 15, 2025Capital Medical University, Prime Gene Therapeutics Co., Ltd.
NCT06837233Phase 2Mar 12, 2025Capital Medical University, Prime Gene Therapeutics Co., Ltd.
NCT06587685Phase 3Mar 15, 2024Capital Medical University, China Medical University, Fujian Medical University, Guangzhou Medical University, Hebei University, Nanchang University, Nanyang Central Hospital, Ningbo University, Peking University, Prime Gene Therapeutics Co., Ltd., Shanxi Medical University, Southern Medical University
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Capital Medical UniversityAcademic/Hospital3022024
Prime Gene Therapeutics Co., Ltd.For profit3322024
China Medical UniversityAcademic/Hospital1012024
Fujian Medical UniversityAcademic/Hospital1012024
Guangzhou Medical UniversityAcademic/Hospital1012024
Hebei UniversityAcademic/Hospital1012024
Nanchang UniversityAcademic/Hospital1012024
Nanyang Central HospitalAcademic/Hospital1012024
Ningbo UniversityAcademic/Hospital1012024
Peking UniversityAcademic/Hospital1012024
Shanxi Medical UniversityAcademic/Hospital1012024
Southern Medical UniversityAcademic/Hospital1012024
12 organizations
Page 1 / 1